Correlation of C-myc and HER-2/neu amplification and expression with histopathologic variables in uterine corpus cancer.

[1]  S. Cha,et al.  HER-2/neu expression: A major prognostic factor in endometrial cancer , 1992 .

[2]  J. Foekens,et al.  Prognostic factors in human primary breast cancer: Comparison of c-myc and HER2/neu amplification , 1992, The Journal of Steroid Biochemistry and Molecular Biology.

[3]  J. Foekens,et al.  c-myc amplification is a better prognostic factor than HER2/neu amplification in primary breast cancer. , 1992, Cancer research.

[4]  I. Laird-Offringa.  What determines the instability of c‐myc proto‐oncogene mRNA? , 1992, BioEssays : news and reviews in molecular, cellular and developmental biology.

[5]  G. Sutton,et al.  Immunohistochemical Study of HER-2/neu, Epidermal Growth Factor Receptor, and Steroid Receptor Expression in Normal and Malignant Endometrium , 1992, Obstetrics and gynecology.

[6]  T. Maudelonde,et al.  Decrease of c-erbB-2 and c-myc RNA levels in tamoxifen-treated breast cancer. , 1991, Oncogene.

[7]  J. Bishop.  Molecular themes in oncogenesis , 1991, Cell.

[8]  L. Strong,et al.  Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. , 1990, Science.

[9]  K. Hatch,et al.  Oncogene alterations in endometrial carcinoma. , 1990, Gynecologic oncology.

[10]  C. Cordon-Cardo,et al.  Expression of the HER-2/neu proto-oncogene in normal human adult and fetal tissues. , 1990, Oncogene.

[11]  B. Katzenellenbogen,et al.  Hormonal modulation of HER-2/neu protooncogene messenger ribonucleic acid and p185 protein expression in human breast cancer cell lines. , 1990, Cancer research.

[12]  S. Cha,et al.  DNA ploidy in endometrial carcinoma: major objective prognostic factor. , 1990, Mayo Clinic proceedings.

[13]  H. Sasano,et al.  Serous papillary adenocarcinoma of the endometrium. Analysis of proto‐oncogene amplification, flow cytometry, estrogen and progesterone receptors, and immunohistochemistry , 1990, Cancer.

[14]  A. Ullrich,et al.  Expression of the p185 encoded by her2 oncogene in normal and transformed human tissues , 1990, International journal of cancer.

[15]  W Godolphin,et al.  Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. , 1989, Science.

[16]  K. Chandy,et al.  Characterization of lymphoid tumors induced by a recombinant murine retrovirus carrying the avian v-myc oncogene. Identification of novel (B-lymphoid) tumors in the thymus. , 1988, Journal of immunology.

[17]  Robert A. Edwards,et al.  High level expression of fms proto-oncogene mRNA is observed in clinically aggressive human endometrial adenocarcinomas. , 1988, International journal of radiation oncology, biology, physics.

[18]  G. Sutton,et al.  Steroid receptors and clinical outcome in patients with adenocarcinoma of the endometrium. , 1988, American journal of obstetrics and gynecology.

[19]  Cori Bargmann,et al.  The neu oncogene encodes an epidermal growth factor receptor-related protein , 1986, Nature.

[20]  H. Varmus,et al.  Homogeneously staining chromosomal regions contain amplified copies of an abundantly expressed cellular oncogene (c-myc) in malignant neuroendocrine cells from a human colon carcinoma. , 1983, Proceedings of the National Academy of Sciences of the United States of America.

[21]  A. NovoGonzalez,et al.  [Adenocarcinoma of the uterus]. , 1960, Clinica y laboratorio.

[22]  R. Bast,et al.  Overexpression of HER-2/neu in endometrial cancer is associated with advanced stage disease. , 1991 .

[23]  D. Spandidos,et al.  The role of ras and myc oncogenes in human solid tumours and their relevance in diagnosis and prognosis (review). , 1990, Anticancer research.

[24]  W. J. Brammar,et al.  Alterations to either c-erbB-2(neu) or c-myc proto-oncogenes in breast carcinomas correlate with poor short-term prognosis. , 1987, Oncogene.

[25]  P. Disaia,et al.  Clinical Gynecologic Oncology , 1981 .